New Drug Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Breakthrough
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Latest breakthroughs in cancer research, treatment, and prevention
643 articles
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
Swiss researchers completed a 74-patient phase 2 trial exploring optimal dosing schedules for dual checkpoint blockade in metastatic renal cell carcinoma.
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
A new perspective in Nature Cancer outlines how genetically engineered bacteria can target and destroy tumors from within.
A completed French trial explores how gut and airway microbiota, blood, and sputum biomarkers relate to immunotherapy outcomes in metastatic NSCLC.
A large genomic study finds mesenchymal glioblastoma responds better to immune checkpoint blockade, opening a path to smarter patient selection.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Inhibiting the mitophagy kinase PINK1 amplifies mitochondrial ROS, activating a BAX-caspase-GSDME cascade that destroys neuroblastoma cells via pyroptosis.
END-seq reveals ALT-positive cancer telomeres share canonical 5′ ATC termini with normal cells, but harbor uniquely abundant single-stranded DNA regions.
A landmark WGS study of 1,804 myeloid neoplasia patients uncovers how telomere length varies by mutation type and cancer subtype.